Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
0.8201
+0.0101 (1.25%)
Apr 29, 2025, 4:00 PM EDT - Market closed
CNTB Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for CNTB stock has a target of 8.00, which predicts an increase of 875.49% from the current stock price of 0.82.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for CNTB is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 1 | 1 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 1 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +875.49% | Apr 1, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +875.49% | Mar 31, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +875.49% | Sep 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $8 | Strong Buy | Reiterates | $8 | +875.49% | Jun 13, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $7 → $8 | Strong Buy | Maintains | $7 → $8 | +875.49% | Apr 17, 2024 |
Financial Forecast
Revenue This Year
n/a
from 26.03M
Revenue Next Year
73.96M
EPS This Year
-7.23
from -0.28
EPS Next Year
-6.49
from -7.23
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 152.3M | 282.2M | ||
| Avg | n/a | 74.0M | 264.6M | ||
| Low | n/a | n/a | 245.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 281.5% | ||
| Avg | - | - | 257.8% | ||
| Low | - | - | 231.5% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -6.35 | -3.29 | -1.38 | ||
| Avg | -7.23 | -6.49 | -2.59 | ||
| Low | -7.96 | -9.40 | -3.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.